Even in patients in which dual directed therapy may be used, antigen escape has been reported in both CD19- and CD 22-directed CAR T-cell therapy in pediatric ALL, further highlighting the need for novel strategies to improve tumor cell targeting. This evidence concerns the gene CD19 and neoplasm.